Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00254696
Status:
COMPLETED
Last Update Posted:
2011-04-15
First Post:
2005-11-14
Brief Title:
Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases ESBLs
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
Association of Antibiotic Utilization Measures and Control of Extended-spectrum-lactamases ESBLs
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the value of using piperacillintazobactam in reducing the cases of ESBL producing E coli or K pneumoniae colonization and infection
To determine the acquisition rate of ESBL producing E coli or K pneumoniae both pre and post intervention in the selected medical centers
To determine the acquisition rate of ESBL producing E coli or K pneumoniae both pre and post intervention in the selected medical centers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None